CITIC SEC released a research report highlighting that inflammatory bowel disease (IBD), a challenging autoimmune disorder, presents significant unmet clinical needs and vast market potential. Despite the growing range of therapeutic targets in IBD, the clinical remission rate (placebo-adjusted) during the induction phase remains limited, typically ranging between 10%-20%, with high-dose groups of approved drugs often achieving above 15%. The IBD treatment landscape is evolving rapidly, with an urgent demand for novel mechanisms and therapies, marked by the rise of long-acting injectables and diversified oral treatments. Multinational corporations (MNCs) are accelerating their IBD sector investments, while Chinese biopharma innovators are gaining traction in differentiated pipelines. The report recommends focusing on new targets and mechanisms, closely monitoring clinical trial progress, and tracking key data readouts.

**IBD: A Complex Disease with High Prevalence** Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a complex autoimmune condition with unclear pathogenesis and no cure, leaving substantial unmet needs. According to public data, over 10 million people worldwide suffer from CD or UC, with China’s IBD patient population projected to reach 1.5 million by 2025. Organovo forecasts the global IBD market (UC + CD) to hit $100 billion by 2032.

**IBD Treatments: Evolving Landscape with Long-Acting Injectables and Oral Therapies** Since the 1998 approval of TNF-α inhibitor infliximab for CD, targeted therapies like adalimumab, vedolizumab, and ustekinumab have expanded IBD’s market potential. The field is now dominated by IL-23 p19 antibodies and JAK inhibitors. However, induction-phase clinical remission rates (placebo-adjusted) remain modest, mostly at 10%-20%, with high-dose groups exceeding 15%.

Emerging therapies show promise: TL1A-targeting antibodies, such as Sanofi and Teva’s duvakitug, demonstrated a 47.8% clinical remission rate (27% placebo-adjusted) in UC and 48% endoscopic remission (35% placebo-adjusted) in CD during Phase II trials. Other mechanisms under exploration include inflammation modulation, T-cell regulation, and gut barrier repair. Oral small molecules (S1P, JAK, TYK2 inhibitors) are gaining ground due to convenience and unique mechanisms, becoming key options for step-up therapy.

**MNCs Expand IBD Footprint; Chinese Innovators Emerge** With IBD’s high patient burden and modest 30%-50% maintenance-phase remission rates, MNCs are aggressively investing. Established players are reinforcing dominance with new products, chronic disease leaders are pivoting resources, and oncology-focused firms are entering via BD or acquisitions. High-quality clinical-stage IBD assets are estimated to command over $2 billion in transactions.

Chinese companies are aligning with global trends while showcasing innovation: Everest Medicines’ S1P modulator etrasimod (under NDA review in China) addresses first-line oral therapy gaps; Innovent’s IL-23 p19 antibody and Hengrui’s JAK1 inhibitor posted strong Phase II data; InnoCare and InventisBio’s selective TYK2 inhibitors aim for safety breakthroughs; while ChenXin Pharmaceutical and HeMei Pharma explore cutting-edge NLRP3 and PDE4 targets.

**Risk Factors**: Clinical trial delays/failures; intensifying competition; commercialization hurdles; regulatory changes.